Plasmid DNA is an extrachromosomal DNA molecule that is separate from the chromosomal DNA in a cell. Plasmid DNA can replicate independently and have origins of replication on their DNA that allows them to replicate separately from the genomic DNA. Plasmid DNA is widely used in genetic engineering processes and is used in medications for gene therapy.
The Plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 35% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Plasmid DNA manufacturing key trends include increasing investment and funding for cell and gene therapy development. Advancements in process development and scaling-up plasmid DNA manufacturing operations are also driving market growth. Commercial applications of plasmid DNA are increasing in areas like vaccines, cancer immunotherapy and regenerative medicines. Newer technologies using continuous manufacturing platforms are enabling more efficient plasmid DNA production. Growing prevalence of chronic diseases is expected to increase demand for plasmid DNA engineered therapeutics, supporting market expansion through 2030.
Strength: Plasmid DNA has wide applications in areas like gene therapy, DNA vaccination and genetic engineering which is driving the market growth. It is cost effective compared to alternative DNA production methods.
Weakness: Regulations around genetic engineering and cell and gene therapy can hamper the market growth. Production of high-quality and high-volume plasmids require advanced technologies which increases production costs.
Opportunity: Increasing R&D investment in biopharmaceutical industry and rising demand for plasmid DNA in drug discovery and development process present lucrative growth opportunities. Growing stem cell research also offers potential opportunities.
Threats: Issues related to plasmid design, construction and optimization can affect product development timelines. Intense competition from market players can also threaten individual organization’s market position.
The Global Plasmid DNA Manufacturing Market Size is expected to witness high growth at a CAGR of 35% over the forecast period, due to increasing investment in cell and gene therapy research.
Regional analysis: North America dominated the market in 2022 and is expected to remain the highest revenue generating region during the forecast period. This is attributed to presence of major market players and growing biotechnology research in the US. Asia Pacific is projected to exhibit the fastest growth rate during the forecast period due to improving healthcare infrastructure and increasing number of CROs and biologics manufacturers in the region.
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing. Major players are focusing on R&D to develop efficient manufacturing processes and optimize plasmid production.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it